Stay updated on Emixustat in Stargardt Macular Atrophy Clinical Trial
Sign up to get notified when there's something new on the Emixustat in Stargardt Macular Atrophy Clinical Trial page.

Latest updates to the Emixustat in Stargardt Macular Atrophy Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has undergone significant content removal related to a pharmacodynamics study of emixustat hydrochloride for Stargardt disease, including detailed descriptions of the study's design, criteria, and investigators. The only notable addition is a reference to the study's version revision.SummaryDifference26%
- Check67 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check103 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Emixustat in Stargardt Macular Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emixustat in Stargardt Macular Atrophy Clinical Trial page.